Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer
Abstract
:1. Introduction
2. Results
2.1. Expression of Hormone Receptors in EOC Tissues
2.2. Hierarchical Clustering Analysis of Hormone Receptors in EOCs
2.3. Association between TIL Infiltration and EOC Subgroups Based on Hormone Receptors
2.4. Association between PD-1 or Programmed Cell Death Protein-Ligand1 (PD-L1) Expression and EOC Subgroups Based on Hormone Receptors
2.5. NanoString Analysis of the Triple Dominant Group
3. Discussion
4. Materials and Methods
4.1. Patients and Tumor Specimens
4.2. Tissue Microarray and Immunohistochemistry
4.3. Evaluation of Immunohistochemical (IHC) Staining
4.4. mRNA-seq Data Analysis
4.5. RNA Extraction and Quality Control
4.6. Quantification of Gene Expression and Analysis of Differentially Expressed Genes (DEGs) Using the NanoString nCounter Platform
4.7. Network Analysis
4.8. Gene Ontology Analysis
4.9. Statistical Analysis
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Torre, L.A.; Trabert, B.; DeSantis, C.E.; Mph, K.D.M.; Samimi, G.; Runowicz, C.D.; Gaudet, M.M.; Jemal, A.; Siegel, R.L. Ovarian cancer statistics. CA A Cancer J. Clin. 2018, 68, 284–296. [Google Scholar] [CrossRef] [PubMed]
- Hennessy, B.T.; Coleman, R.L.; Markman, M. Ovarian cancer. Lancet 2009, 374, 1371–1382. [Google Scholar] [CrossRef]
- Weiss, L.; Huemer, F.; Mlineritsch, B.; Greil, R. Immune checkpoint blockade in ovarian cancer. Memo-Mag. Eur. Med Oncol. 2016, 9, 82–84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.; Gray, H.; Regnani, G.; Schlienger, K.; et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N. Engl. J. Med. 2003, 348, 203–213. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gasparri, M.L.; Attar, R.; Palaia, I.; Perniola, G.; Marchetti, C.; Di Donato, V.; Farooqi, A.A.; Papadia, A.; Panici, P.B. Tumor infiltrating lymphocytes in ovarian cancer. Asian Pac. J. Cancer Prev. 2015, 16, 3635–3638. [Google Scholar] [CrossRef] [Green Version]
- Wouters, M.C.A.; Komdeur, F.L.; Workel, H.H.; Klip, H.G.; Plat, A.; Kooi, N.M.; Wisman, G.B.A.; Mourits, M.J.E.; Arts, H.J.G.; Oonk, M.H.M.; et al. Treatment Regimen, Surgical Outcome, and T-cell Dif-ferentiation Influence Prognostic Benefit of Tumor-Infiltrating Lymphocytes in High-Grade Serous Ovarian Cancer. Clin. Cancer Res. 2016, 22, 714–724. [Google Scholar] [CrossRef] [Green Version]
- Ou, Y.; Cannon, M.J.; Nakagawa, M. Regulatory T Cells in Gynecologic Cancer. MOJ Immunol. 2018, 6, 34–42. [Google Scholar] [CrossRef]
- Mizushima, T.; Miyamoto, H. The Role of Androgen Receptor Signaling in Ovarian Cancer. Cells 2019, 8, 176. [Google Scholar] [CrossRef] [Green Version]
- McDonnel, A.C.; Van Kirk, E.A.; Isaak, D.D.; Murdoch, W.J. Inhibitory Effects of Progesterone on Plasma Membrane Fluidity and Tumorigenic Potential of Ovarian Epithelial Cancer Cells. Exp. Biol. Med. 2003, 228, 308–314. [Google Scholar] [CrossRef]
- Ho, S.-M. Estrogen, Progesterone and Epithelial Ovarian Cancer. Reprod. Biol. Endocrinol. 2003, 1, 73. [Google Scholar] [CrossRef] [Green Version]
- Coenen, C.M.; Thomas, C.M.; Borm, G.F.; Hollanders, J.M.; Rolland, R. Changes in androgens during treatment with four low-dose contraceptives. Contraception 1996, 53, 171–176. [Google Scholar] [CrossRef]
- Arias-Pulido, H.; Smith, H.O.; Joste, N.E.; Bocklage, T.; Qualls, C.R.; Chavez, A.; Prossnitz, E.R.; Verschraegen, C.F. Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors. Gynecol. Oncol. 2009, 114, 480–485. [Google Scholar] [CrossRef] [Green Version]
- Pierdominici, M.; Maselli, A.; Colasanti, T.; Giammarioli, A.M.; Delunardo, F.; Vacirca, D.; Sanchez, M.; Giovannetti, A.; Malorni, W.; Ortona, E. Estrogen receptor profiles in human peripheral blood lymphocytes. Immunol. Lett. 2010, 132, 79–85. [Google Scholar] [CrossRef]
- Kovats, S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell. Immunol. 2015, 294, 63–69. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mantalaris, A.; Panoskaltsis, N.; Sakai, Y.; Bourne, P.; Chang, C.; Messing, E.M.; Wu, J.H.D. Localiza-tion of androgen receptor expression in human bone marrow. J. Pathol. 2001, 193, 361–366. [Google Scholar] [CrossRef]
- Arruvito, L.; Giulianelli, S.; Flores, A.C.; Paladino, N.; Barboza, M.; Lanari, C.; Fainboim, L. NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. J. Immunol. 2008, 180, 5746–5753. [Google Scholar] [CrossRef] [Green Version]
- Dosiou, C.E.; Hamilton, A.; Pang, Y.; Overgaard, M.T.; Tulac, S.; Dong, J.; Thomas, P.; Giudice, L.C. Expression of membrane progesterone receptors on human T lymphocytes and Jurkat cells and activation of G-proteins by progesterone. J. Endocrinol. 2007, 196, 67–77. [Google Scholar] [CrossRef]
- Ghebeh, H.; Mohammed, S.; Al-Omair, A.; Qattant, A.; Lehe, C.; Al-Qudaihi, G.; Elkum, N.; Al-shabanah, M.; Bin Amer, S.; Tulbah, A.; et al. The B7-H1 (PD-L1) T Lymphocyte-Inhibitory Molecule Is Expressed in Breast Cancer Patients with Infiltrating Ductal Carcinoma: Correlation with Important High-Risk Prognostic Factors. Neoplasia 2006, 8, 190–198. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duma, D.; Jewell, C.M.; Cidlowski, J.A. Multiple glucocorticoid receptor isoforms and mechanisms of post-translational modification. J. Steroid Biochem. Mol. Biol. 2006, 102, 11–21. [Google Scholar] [CrossRef]
- Ling, J.; Kumar, R. Crosstalk between NFkB and glucocorticoid signaling: A potential target of breast cancer therapy. Cancer Lett. 2012, 322, 119–126. [Google Scholar] [CrossRef]
- Anderson, D.M.; Maraskovsky, E.; Billingsley, W.L.; Dougall, W.C.; Tometsko, M.E.; Roux, E.R.; Teepe, M.C.; DuBose, R.F.; Cosman, D.; Galibert, L.J. A homologue of the TNF receptor and its ligand en-hance T-cell growth and dendritic-cell function. Nat. Cell Biol. 1997, 390, 175–179. [Google Scholar] [CrossRef]
- Frasor, J.; Weaver, A.; Pradhan, M.; Dai, Y.; Miller, L.D.; Lin, C.Y.; Stanculescu, A. Positive cross-talk between estro-gen receptor and NF-kappaB in breast cancer. Cancer Res. 2009, 69, 8918–8925. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Burg, V.D.; der Saag, P.T.V. Endocrinology and paracrinology: Nuclear factor-kappa-B/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. Mol. Hum. Reprod. 1996, 2, 433–438. [Google Scholar] [CrossRef]
- Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014, 15, 550. [Google Scholar] [CrossRef] [Green Version]
- Zhou, G.; Soufan, O.; Ewald, J.; Hancock, R.E.W.; Basu, N.; Xia, J. NetworkAnalyst 3.0: A visual ana-lytics platform for comprehensive gene expression profiling and meta-analysis. Nucleic Acids Res. 2019, 47, W234–W241. [Google Scholar] [CrossRef] [Green Version]
- Raudvere, U.; Kolberg, L.; Kuzmin, I.; Arak, T.; Adler, P.; Peterson, H.; Vilo, J. g:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update). Nucleic Acids Res. 2019, 47, W191–W198. [Google Scholar] [CrossRef] [Green Version]
- Sutmuller, R.P.; Morgan, M.E.; Netea, M.G.; Grauer, O.; Adema, G.J. Toll-like receptors on regulatory T cells: Expanding immune regulation. Trends Immunol. 2006, 27, 387–393. [Google Scholar] [CrossRef]
- Hoeppli, R.E.; Wu, D.; Cook, L.; Levings, M.K. The Environment of Regulatory T Cell Biology: Cyto-kines, Metabolites, and the Microbiome. Front. Immunol. 2015, 6, 61. [Google Scholar] [CrossRef] [Green Version]
- Kitagawa, Y.; Sakaguchi, S. Molecular control of regulatory T cell development and function. Curr. Opin. Immunol. 2017, 49, 64–70. [Google Scholar] [CrossRef]
- Feng, Z.; Wentao, Y.; Bi, R.; Xiaojun, C.; Chen, X.; Yang, W.; Wu, X. A clinically applicable molecular classification for high-grade serous ovarian cancer based on hormone receptor expression. Sci. Rep. 2016, 6, 25408. [Google Scholar] [CrossRef] [Green Version]
- Van Kruchten, M.; van der Marel, P.; de Munck, L.; Hollema, H.; Arts, H.; Timmer-Bosscha, H.; de Vries, E.; Hospers, G.; Reyners, A. Hormone receptors as a marker of poor survival in epithelial ovarian cancer. Gynecol. Oncol. 2015, 138, 634–639. [Google Scholar] [CrossRef] [PubMed]
- Ogara, M.F.; A Rodríguez-Seguí, S.; Marini, M.; Nacht, A.S.; Stortz, M.; Levi, V.; Presman, D.; Vicent, G.P.; Pecci, A. The glucocorticoid receptor interferes with progesterone receptor-dependent genomic regula-tion in breast cancer cells. Nucleic Acids Res. 2019, 47, 10645–10661. [Google Scholar] [CrossRef] [PubMed]
- Wan, Y.; Nordeen, S.K. Overlapping but distinct profiles of gene expression elicited by glucocorti-coids and progestins. Recent Prog. Horm. Res. 2003, 58, 199–226. [Google Scholar] [CrossRef] [PubMed]
- Beato, M.; Chávez, S.; Truss, M. Transcriptional regulation by steroid hormones. Steroids 1996, 61, 240–251. [Google Scholar] [CrossRef]
- De Stefano, I.; Zannoni, G.F.; Prisco, M.G.; Fagotti, A.; Tortorella, L.; Vizzielli, G.; Mencaglia, L.; Scambia, G.; Gallo, D. Cytoplasmic ex-pression of estrogen receptor beta (ERbeta) predicts poor clinical outcome in advanced serous ovarian cancer. Gynecol. Oncol. 2011, 122, 573–579. [Google Scholar] [CrossRef]
- Curiel, T.J.; Coukos, G.; Zou, L.; Alvarez, X.; Cheng, P.; Mottram, P.; Evdemon-Hogan, M.; Cone-jo-Garcia, J.; Zhang, L.; Burow, M.; et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 2004, 10, 942–949. [Google Scholar] [CrossRef]
- Stary, G.; Klein, I.; Bauer, W.; Koszik, F.; Reininger, B.; Kohlhofer, S.; Gruber, K.; Skvara, H.; Jung, T.; Stingl, G. Glucocorticosteroids Modify Langerhans Cells To Produce TGF-β and Expand Regulatory T Cells. J. Immunol. 2010, 186, 103–112. [Google Scholar] [CrossRef]
- Hou, Y.; Feng, Q.; Xu, M.; Li, G.-S.; Liu, X.-N.; Sheng, Z.; Zhou, H.; Ma, J.; Wei, Y.; Sun, Y.-X.; et al. High-dose dexamethasone corrects impaired myeloid-derived suppressor cell function via Ets1 in immune thrombocytopenia. Blood 2016, 127, 1587–1597. [Google Scholar] [CrossRef] [Green Version]
- Huang, S.J.; Cidlowski, J.A. Phosphorylation status modulates Bcl-2 function during glucocorticoid-induced apoptosis in T lymphocytes. FASEB J. 2002, 16, 825–832. [Google Scholar] [CrossRef]
- Bereshchenko, O.; Coppo, M.; Bruscoli, S.; Biagioli, M.; Cimino, M.; Frammartino, T.; Sorcini, D.; Ve-nanzi, A.; Di Sante, M.; Riccardi, C. GILZ Promotes Production of Peripherally Induced Treg Cells and Mediates the Crosstalk between Glucocorticoids and TGF-β Signaling. Cell Rep. 2014, 7, 464–475. [Google Scholar] [CrossRef] [Green Version]
- Ugor, E.; Prenek, L.; Pap, R.; Berta, G.; Ernszt, D.; Najbauer, J.; Németh, P.; Boldizsár, F.; Berki, T. Glucocorticoid hormone treatment enhances the cytokine production of regulatory T cells by upregulation of Foxp3 expression. Immunobiology 2018, 223, 422–431. [Google Scholar] [CrossRef]
- Walecki, M.; Eisel, F.; Klug, J.; Baal, N.; Paradowska-Dogan, A.; Wahle, E.; Hackstein, H.; Meinhardt, A.; Fijak, M. Androgen receptor modulates Foxp3 expression in CD4+CD25+Foxp3+ regulatory T-cells. Mol. Biol. Cell 2015, 26, 2845–2857. [Google Scholar] [CrossRef]
- Zhang, Y.; Tong, L.; Chen, S.; Wu, W.; Wang, L. Analysis of NFKB2mediated regulation of mecha-nisms underlying the development of Hodgkin’s lymphoma. Mol. Med. Rep. 2018, 17, 8129–8136. [Google Scholar]
- Lee, E.G.; Boone, D.L.; Chai, S.; Libby, S.L.; Chien, M.; Lodolce, J.P.; Ma, A. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 2000, 289, 2350–2354. [Google Scholar] [CrossRef]
- Song, X.-T.; Kabler, K.E.; Shen, L.; Rollins, L.; Huang, X.F.; Chen, S.-Y. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell–mediated suppression. Nat. Med. 2008, 14, 258–265. [Google Scholar] [CrossRef]
- Generali, D.; Bates, G.; Berruti, A.; Brizzi, M.P.; Campo, L.; Bonardi, S.; Bersiga, A.; Allevi, G.; Milani, M.; Aguggini, S.; et al. Immunomodulation of FOXP3+ Regulatory T Cells by the Aromatase Inhibitor Let-rozole in Breast Cancer Patients. Clin. Cancer Res. 2009, 15, 1046–1051. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bates, G.J.; Fox, S.B.; Han, C.; Leek, R.D.; Garcia, J.F.; Harris, A.L.; Banham, A.H. Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse. J. Clin. Oncol. 2006, 24, 5373–5380. [Google Scholar] [CrossRef]
- Salgado, R.; Denkert, C.; Demaria, S.; Sirtaine, N.; Klauschen, F.; Pruneri, G.; Wienert, S.; Eynden, G.V.D.; Baehner, F.L.; Penault-Llorca, F.; et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an International TILs Working Group. Ann. Oncol. 2015, 26, 259–271. [Google Scholar] [CrossRef]
Variables | Univariate Analysis | Multivariate Analysis | ||
---|---|---|---|---|
Hazard Ratio [95%CI *] | p-Value | Hazard Ratio [95%CI *] | p-Value | |
FIGO stage (III-IV) | 6.427 [3.335–12.386] | <0.001 | 4.604 [2.260–9.380] | <0.001 |
Cell type (Serous) | 0.337 [0.202–0.561] | <0.001 | 0.525 [0.294–0.939] | 0.030 |
Tumor grade (Poor) | 1.949 [1.286–2.954] | 0.002 | 1.646 [1.074–2.518] | 0.022 |
CA 125 + (>35 U/mL) | 2.397 [1.208–4.753] | 0.012 | 1.004 [0.471–2.141] | 0.992 |
Age (>50) | 1.577 [1.064–2.339] | 0.023 | 1.231 [0.810–1.872] | 0.330 |
ERα + a | 1.625 [1.038–2.542] | 0.034 | 1.363 [0.842–2.207] | 0.207 |
AR + b | 1.887 [1.245–2.860] | 0.002 | 1.546 [0.998–2.396] | 0.051 |
PR + c | 1.201 [0.794–1.815] | 0.386 | NA | |
GR + d | 2.610 [1.143–5.958] | 0.023 | 1.892 [0.823–4.351] | 0.133 |
ERβ + e | 1.824 [1.226–2.714] | 0.003 | 1.403 [0.918–2.543] | 0.118 |
Heatmap (Triple dominant) | 2.668 [1.728–4.118] | <0.001 | 2.176 [1.361–3.487] | 0.001 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Han, G.H.; Hwang, I.; Cho, H.; Ylaya, K.; Choi, J.-A.; Kwon, H.; Chung, J.-Y.; Hewitt, S.M.; Kim, J.-H. Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer. Int. J. Mol. Sci. 2021, 22, 5714. https://doi.org/10.3390/ijms22115714
Han GH, Hwang I, Cho H, Ylaya K, Choi J-A, Kwon H, Chung J-Y, Hewitt SM, Kim J-H. Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer. International Journal of Molecular Sciences. 2021; 22(11):5714. https://doi.org/10.3390/ijms22115714
Chicago/Turabian StyleHan, Gwan Hee, Ilseon Hwang, Hanbyoul Cho, Kris Ylaya, Jung-A Choi, Hyunja Kwon, Joon-Yong Chung, Stephen M. Hewitt, and Jae-Hoon Kim. 2021. "Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer" International Journal of Molecular Sciences 22, no. 11: 5714. https://doi.org/10.3390/ijms22115714